Feb 15 (Reuters) - Eli Lilly LLY.N
* Eli Lilly - additional results from pivotal ra-beam study published in New England Journal of Medicine
* Eli Lilly - results show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
* Eli Lilly- through 52-week period, serious adverse event rates were 8 percent for baricitinib and 4 percent for adalimumab
* Eli Lilly - total of 5 deaths were reported in study Source text for Eikon: ID:nCNWGd3vLa Further company coverage: INCY.O